Influenza A Viral Infections Drug Development Pipeline Review, 2018
- Pages: 188
- Published: April 2018
- Report Code: GBIHC032IDB
This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.
Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.
Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.
Scope
– Which companies are the most active within the pipeline for influenza A viral infections?
– Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
AbbVie Inc
Adimmune Corp
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Aphios Corp
AusBio Ltd
Beijing Minhai Biotechnology Co Ltd
BioCryst Pharmaceuticals Inc
BiondVax Pharmaceuticals Ltd
Cadila Healthcare Ltd
Celltrion Inc
CEL-SCI Corp
Cilian AG
Cocrystal Pharma Inc
ContraFect Corp
Curevac AG
Emergent BioSolutions Inc
EpiVax Inc
Etubics Corp
FluGen Inc
Gemmus Pharma Inc
Genentech Inc
GlaxoSmithKline Plc
Hemispherx Biopharma Inc
iBio Inc
Influenza A Virus, H1N1 Subtype Infections
Influenza A Virus, H3N2 Subtype Infections
Influenza A Virus, H5N1 Subtype Infections
Influenza A Virus, H7N9 Subtype Infections
Inovio Pharmaceuticals Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Kineta Inc
Kyowa Hakko Kirin Co Ltd
Lakewood-Amedex Inc
Medicago Inc
Medigen Vaccine Biologics Corp
MedImmune LLC
Microbiotix Inc
Moderna Therapeutics Inc
Mucosis BV (Inactive)
NanoBio Corp
NanoViricides Inc
Novavax Inc
Ology Bioservices Inc
OPKO Health Inc
PaxVax Inc
PeptiDream Inc
Recce Ltd
Sanofi
Sanofi Pasteur SA
Sarepta Therapeutics Inc
Shionogi & Co Ltd
SK Chemicals Co Ltd
TechnoVax Inc
Touchlight Genetics Ltd
Vaccibody AS
Vaxart Inc
Vaxine Pty Ltd
VBI Vaccines Inc
VirionHealth Ltd
Visterra Inc
Vivaldi Biosciences Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.